₹873.05▲0.01%
Overview of Natco Pharma Ltd
Natco Pharma Ltd has invested USD 3 million in a funding round for hygiene and wellness brand Pee Safe, out of the total round size of USD 6 million.
Natco Pharma Faces Antitrust Lawsuit in the US - 11 Sep, 2023
Natco Pharma Ltd has been named as a defendant in an antitrust lawsuit filed by Louisiana Health Service & Indemnity Company and HMO Louisiana Inc. regarding Pomalidomide (Pomalyst), causing its shares to drop by 5.34%.
Natco Pharma Named in Antitrust Lawsuit - 09 Sep, 2023
Natco Pharma, along with other drug makers, has been named as defendants in an antitrust lawsuit regarding a generic cancer treatment drug in the US. The company believes the matter is without merit.
Natco Pharma Named Defendant in Antitrust Lawsuit - 08 Sep, 2023
Natco Pharma Ltd's involvement in an antitrust lawsuit regarding cancer drug Pomalidomide caused its share price to slump by over 3%.
Natco Pharma Invests $2 Million in ISCA Inc. - 31 Aug, 2023
Natco Pharma Ltd has made a strategic investment of $2 million in Delaware-based ISCA Inc. for bio control of pests, acquiring a 5.79% stake.
Natco Pharma Declares Interim Dividend of Rs 7 per Share - 22 Aug, 2023
Natco Pharma Ltd has announced an interim dividend of Rs 7 per equity share with a face value of Rs 2. The record date is August 22.
Krishna Institute of Medical Sciences and Natco Pharma among top bets in growing diagnostics sector - 21 Aug, 2023
The organised companies' market share in the Indian diagnostics sector has increased from 15% to 17%. Krishna Institute of Medical Sciences and Natco Pharma are recommended as top picks.
Natco Pharma to Trade Ex-Dividend Soon - 17 Aug, 2023
Natco Pharma Limited is set to trade ex-dividend in the next 4 days, with an upcoming dividend of ₹7.00 per share, increased from last year's total dividends per share of ₹5.50. The company paid out just 20% of its profit and 16% of its free cash flow last year, indicating a sustainable dividend.
Natco Pharma to Increase Dividend by 100% - 12 Aug, 2023
Natco Pharma Limited has announced a 100% increase in its periodic dividend, taking the annual payment to 0.6% of the current stock price. The company's stock price has increased by 36% in the last three months, but the dividend yield is below industry standards. While earnings per share are forecasted to rise by 99.5%, investors should be cautious about the company's unstable dividend history.
Natco Pharma Ltd Exhibits Overbought Characteristics - 10 Aug, 2023
According to ETMarkets, Natco Pharma Ltd is one of the 10 stocks exhibiting notable overbought characteristics based on their RSI values.
Natco Pharma Reports Strong Q1 Results - 09 Aug, 2023
Natco Pharma Ltd reported a 31.2% rise in consolidated net profit at Rs 420.3 crore for Q1, and declared an interim dividend of Rs 7 per equity share of Rs 2 each for FY24. The stock also achieved a 52-week high of Rs 895.
Natco Pharma Shares Reach New High - 08 Aug, 2023
Shares of Natco Pharma have reached a new 52-week high of Rs 879 and are trading above their IPO price.
Natco Pharma Stock Sees Gains and Overbought RSI - 31 Jul, 2023
Natco Pharma Ltd's stock saw gains between 1-2%, while its RSI reached an overbought zone of 84.26 on July 28.
Natco Pharma Stock Shows Strength Amid Positive Momentum in Pharma Sector - 29 Jul, 2023
The long-term chart of the Pharma sector indicates that it has bottomed out, and Natco Pharma's stock is showing signs of strength. It might be worth considering for long-term investors looking to take advantage of the positive momentum in the Pharma sector.
Natco Pharma Submits ANDA to FDA for Generic Version of Erdafitinib Tablets - 26 Jul, 2023
Natco Pharma Ltd's shares reach a 52-week high of Rs 793.8 and the company submits an abbreviated new drug application (ANDA) to the US FDA for the generic version of Erdafitinib tablets.
Akash Bhanshali Acquires Stake in Natco Pharma - 25 Jul, 2023
Natco Pharma Ltd's shares were trading in the red on the NSE after Akash Bhanshali acquired a 1% stake worth Rs 138 crore.
Natco Pharma's Net Cash Position Increases - 16 Jul, 2023
Natco Pharma Ltd had a net cash position of ₹9.97b as of March 2023, with more cash than debt, indicating it can manage its debt safely.
Natco Pharma Shares Rise on Positive Sentiment and Strong Financial Performance - 26 Jun, 2023
Natco Pharma Ltd's shares rose over 3% due to its robust product pipeline and strong positioning in catering to the growing demand for affordable healthcare. The company's financial performance was also strong with a 52% YoY increase in revenue and a consolidated net profit of Rs 275 crore.
Natco Pharma Ltd experiences strong breakout on daily and weekly charts - 25 Jun, 2023
Natco Pharma Ltd recently had a strong breakout on the daily chart with high volumes, accompanied by a weekly breakout surpassing the previous five-week high. The momentum indicator RSI has shown a positive crossover, confirming a buy signal. The stock has support at 640 and potential targets for the upside are 750.
Natco Pharma Ltd exhibits bullish MACD crossover - 23 Jun, 2023
Natco Pharma, a pharmaceutical company focused on generic drugs, has shown a bullish MACD crossover. With a strong product pipeline and track record, it is well-positioned to meet the growing demand for affordable healthcare solutions.
Source: S&P Global Market Intelligence
0.34%
Downside
Day's Volatility:3.02%
Upside
2.69%
42.50%
Downside
52 Weeks Volatility:48.79%
Upside
6.29%
Returns % | |
1 Month Return | -2.46 % |
3 Month Return | 25.93 % |
1 Year Return | 42.05 % |
Market Stats | |
Previous Close | ₹872.95 |
Open | ₹877.65 |
Volume | 4.17L |
Market Cap | ₹15,635.40Cr |
Organisation | Natco Pharma Ltd |
Headquarters | Hyderabad |
Industry | Pharmaceuticals |
E-voting on shares | Click here to vote |
Fundamentals of Natco Pharma Ltd
Mutual Funds have increased holdings from 8.50% to 9.45% in Jun 2023 quarter
Retail Investor have increased holdings from 23.87% to 24.07% in Jun 2023 quarter
In the last 6 months, NATCOPHARM stock has moved up by 57.1%
Revenue is up for the last 3 quarters, 452.6 Cr → 926.9 Cr (in ₹), with an average increase of 28.2% per quarter
Promoters have increased holdings from 48.84% to 49.76% in Jun 2023 quarter
Netprofit is up for the last 3 quarters, 56.8 Cr → 275.8 Cr (in ₹), with an average increase of 43.1% per quarter
In the last 1 year, NATCOPHARM has outperformed top 5 stocks with highest market-cap in Pharmaceuticals
In the last 3 years, Sun Pharmaceuticals Industries Ltd has given 123.7% return, outperforming this stock by 132.3%
Foreign Institutions have decreased holdings from 11.91% to 11.02% in Jun 2023 quarter
Natco Pharma Ltd in the last 5 years
Lowest (12.51x)
March 27, 2019
Today (19.45x)
September 28, 2023
Industry (47.79x)
September 28, 2023
Highest (90.32x)
April 6, 2022
Funds | Holdings |
![]() | 0.88% |
![]() | 1.48% |
![]() | 2.02% |
![]() | 0.42% |
![]() | 0.9% |
Investors | Holdings % | Prev. 2 periods | 3M change |
---|---|---|---|
Promoter Holdings | 49.76% | 1.88 | |
Foreign Institutions | 11.02% | ||
Mutual Funds | 9.45% | 11.16 | |
Retail Investors | 24.07% | 0.85 | |
Others | 5.7% |
Technicals of Natco Pharma Ltd share
News & Events of Natco Pharma Ltd
Natco Pharma Ltd(NATCOPHARM | Price |
---|---|
52 Week High | ₹928 |
52 Week Low | ₹502 |
Natco Pharma Ltd(NATCOPHARM | Returns |
---|---|
1 Day Returns | 0.1% |
1 Month Returns | -2.46% |
3 Month Returns | 25.93% |
1 Year Returns | 42.05% |